Introduction: Effective treatment of papillary thyroid carcinoma (PTC) is total thyroidectomy which is followed by radioactive iodine therapy (RIT) to ablate pathologic thyroid remnants and treat metastatic tumors. However, there are concerns about possible side effects of RIT on different hormones that are important in different aspects including the immune defense system, cardiovascular system, pregnancy, and reproductive health. This study aimed to assess the impact of RIT on reliable hormonal markers levels including dehydroepiandrosterone sulfate (DHEA-S) and dihydrotestosterone (DHT) in men as well as progesterone and prolactin in women undergoing treatment for PTC.
Material and Methods: 60 patients (30 male and 30 female) who underwent total thyroidectomy due to PTC and aged 25-50 were selected using convenient sampling. Blood samples were collected from each PTC patient before and 60 days after RIT. DHEA-S, DHT, progesterone, and prolactin concentrations were quantified using an enzyme-linked immunosorbent assay kit. The paired t-test was conducted to compare hormonal marker levels before and after RIT.
Results: Our data revealed significant decreases in DHEA-S and DHT levels between pre- and post-RIT (P< 0.001). In contrast, progesterone and prolactin levels increased significantly after RIT (P< 0.001).
Conclusion: The levels of DHEA-S, DHT, progesterone, and prolactin, which reflect testicular and ovarian reserves, were found to change after RIT. The levels of DHEA-S, DHT, progesterone, and prolactin, which reflect testicular and ovarian reserves, were found to change 60 days after RIT. Despite its benefits in treating PTC, RIT can have serious adverse effects including changes in the serum levels of sexual hormones.
Materials and Methods: 60 patients (30 male and 30 female) who underwent total thyroidectomy due to PTC and aged 25-50 were selected using convenient sampling. Blood samples were collected from each PTC patient just before and 60 days after RIT. The concentrations of DHEA-S, DHT, progesterone, and prolactin were quantified using an enzyme-linked immunosorbent assay kit. The paired t-test was conducted to compare hormonal markers levels before and after RIT.
Results: Our data revealed significant decreases in DHEA-S and DHT levels between pre-and post-RIT (P< 0.001). In contrast, progesterone and prolactin levels increased significantly after RIT (P< 0.001).
Conclusions: The levels of DHEA-S, DHT, progesterone, and prolactin, which reflect testicular and ovarian reserves, were found to change after RIT. The levels of DHEA-S, DHT, progesterone, and prolactin, which reflect testicular and ovarian reserves, were found to change 60 days after RIT. Despite its benefits in treating PTC, RIT can have serious adverse effects including changes in the serum levels of sexual hormones. |
- La Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F, Negri E. Thyroid cancer mortality and incidence: a global overview. International journal of cancer. 2015 May 1;136(9):2187-95.
- Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016 Jan 1;26(1):1-33.
- Parvaresh R, Jalili M, Haghparast A, Khoshgard K, Eivazi MT, Ghorbani M. Evaluations for determination of optimum shields in nuclear medicine. Journal of biomedical physics & engineering. 2020 Oct;10(5):651.
- Rosario MD, Jasul Jr GV. Changes in Ovarian Function after Radioactive Iodine among Patients with Differentiated Thyroid Carcinoma at St. Luke's Medical Center, Philippines. Journal of the ASEAN Federation of Endocrine Societies. 2012;27(1):63-.
- Evranos B, Faki S, Polat SB, Bestepe N, Ersoy R, Cakir B. Effects of radioactive iodine therapy on ovarian reserve: a prospective pilot study. Thyroid. 2018 Dec 1;28(12):1702-7.
- Broer SL, Broekmans FJ, Laven JS, Fauser BC. Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications. Human reproduction update. 2014 Sep 1;20(5):688-701.
- Penzias A, Azziz R, Bendikson K, Falcone T, Hansen K, Hill M, Hurd W, Jindal S, Kalra S, Mersereau J, Racowsky C. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertility and sterility. 2020 Dec 1;114(6):1151-7.
- Casson PR, Lindsay MS, Pisarska MD, Carson SA, Buster JE. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Human reproduction. 2000 Oct 1;15(10):2129-32.
- Hassa H, Aydin Y, Ozatik O, Erol K, Ozatik Y. Effects of dehydroepiandrosterone (DHEA) on follicular dynamics in a diminished ovarian reserve in vivo model. Systems biology in reproductive medicine. 2015 May 4;61(3):117-21.
- Agarwal A, Saini V, Gupta M. DHEA: Emerging role in infertility. AOGD. 2015 Apr;99(1):31.
- Bachmann G, Bancroft J, Braunstein G, Burger H, Davis S, Dennerstein L, Goldstein I, Guay A, Leiblum S, Lobo R, Notelovitz M. Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertility and sterility. 2002 Apr 1;77(4):660-5.
- Handelsman DJ, Yeap BB, Flicker L, Martin S, Wittert GA, Ly LP. Age-specific population centiles for androgen status in men. European journal of endocrinology. 2015 Dec;173(6):809-17.
- Swerdloff RS, Dudley RE, Page ST, Wang C, Salameh WA. Dihydrotestosterone: biochemistry, physiology, and clinical implications of elevated blood levels. Endocrine reviews. 2017 Jun 1;38(3):220-54.
- Traish AM. Negative impact of testosterone deficiency and 5α-reductase inhibitors therapy on metabolic and sexual function in men. Sex and Gender Factors Affecting Metabolic Homeostasis, Diabetes and Obesity. 2017:473-526.
- Graham JD, Clarke CL. Physiological action of progesterone in target tissues. Endocrine reviews. 1997 Aug 1;18(4):502-19.
- Lange CA, Yee D. Progesterone and Breast Cancer. Womens Health (Lond). 2008;4(2):151-62.
- Brisken C. Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nature Reviews Cancer. 2013 Jun;13(6):385-96.
- Turankar S, Sonone K, Turankar A. Hyperprolactinaemia and its comparision with hypothyroidism in primary infertile women. Journal of clinical and diagnostic research: JCDR. 2013 May;7(5):794.
- Valvekar U, Lakshmi S, Kumar AN. Hypothyroidism and hyperprolactinemia showed positive correlation in women with primary and secondary infertility. International Journal of Reproduction, Contraception, Obstetrics and Gynecology. 2016 Jul 1;5(7):2079-84.
- Poppe K, Velkeniers B. Thyroid and infertility. Verh K Acad Geneeskd Belg. 2002;64(6):389-99; discussion 400-2.
- Chiesa C, Strigari L, Pacilio M, Richetta E, Cannatà V, Stasi M, Marzola MC, Schillaci O, Bagni O, Maccauro M. Dosimetric optimization of nuclear medicine therapy based on the Council Directive 2013/59/EURATOM and the Italian law N. 101/2020. Position paper and recommendations by the Italian National Associations of Medical Physics (AIFM) and Nuclear Medicine (AIMN). Physica Medica. 2021 Sep 1;89:317-26.
- Yaish I, Azem F, Gutfeld O, Silman Z, Serebro M, Sharon O, Shefer G, Limor R, Stern N, Tordjman KM. A single radioactive iodine treatment has a deleterious effect on ovarian reserve in women with thyroid cancer: results of a prospective pilot study. Thyroid. 2018 Apr 1;28(4):522-7.
- Rezaeyan A, Haddadi GH, Hosseinzadeh M. Evaluating superoxide dismutase (SOD), glutathione (GSH), malondialdehyde (mda) and the histological changes of the lung tissue after γ-Irradiation in Rats. Journal of Advanced Biomedical Sciences. 2016 Aug 10;6(2):235-45.
- Raymond JP, Izembart M, Marliac V, Dagousset F, Merceron RE, Vulpillat M, Vallué G. Temporary ovarian failure in thyroid cancer patients after thyroid remnant ablation with radioactive iodine. The Journal of Clinical Endocrinology & Metabolism. 1989 Jul 1;69(1):186-90.
- Eftekhari M, Takavar A, Ansari Gilani K, Akhzari F, Fard-Esfahani A, Beiki D. Effects of treatment with radioiodine (¹³¹I) on the gonadal function of the hyperthyroid patients. Iran J Nucl Med. 2003;11(2):7-12.
- Wichers M, Benz E, Palmedo H, Biersack HJ, Grünwald F, Klingmüller D. Testicular function after radioiodine therapy for thyroid carcinoma. European journal of nuclear medicine. 2000 Apr;27:503-7.
- Panjari M, Davis SR. DHEA for postmenopausal women: a review of the evidence. Maturitas. 2010 Jun 1;66(2):172-9.
- Cormier C, Souberbielle JC, Kahan A. DHEA in bone and joint diseases. Joint Bone Spine. 2001 Dec 1;68(6):588-94.
- Labrie F, Belanger A, Lin SX, Simard J, Pelletier G, Labrie C. Is dehydroepiandrosterone a hormone?. Journal of Endocrinology. 2005 Nov 1;187(2):169-96.
- Joyce KE, Biggs ML, Djoussé L, Ix JH, Kizer JR, Siscovick DS, Shores MM, Matsumoto AM, Mukamal KJ. Testosterone, dihydrotestosterone, sex hormone–binding globulin, and incident diabetes among older men: the cardiovascular health study. The Journal of Clinical Endocrinology & Metabolism. 2017 Jan 1;102(1):33-9.
- Yeap BB, Alfonso H, Chubb SP, Handelsman DJ, Hankey GJ, Almeida OP, Golledge J, Norman PE, Flicker L. In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality. The Journal of Clinical Endocrinology & Metabolism. 2014 Jan 1;99(1):E9-18.
- Goletiani NV, Keith DR, Gorsky SJ. Progesterone: review of safety for clinical studies. Experimental and clinical psychopharmacology. 2007 Oct;15(5):427.
- Al-Chalabi M, Bass AN, Alsalman I. Physiology, Prolactin. Treasure Island (FL): StatPearls Publishing LLC.; 2022.
- Molitch ME. Diagnosis and treatment of pituitary adenomas: a review. Jama. 2017 Feb 7;317(5):516-24.
- McNatty KP. Relationship between plasma prolactin and the endocrine microenvironment of the developing human antral follicle. Fertility and Sterility. 1979 Oct 1;32(4):433-8.
|
